Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $35 Price Target

Author: Benzinga Newsdesk | December 14, 2023 11:39am

RBC Capital analyst Gregory Renza reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $35 price target.

Posted In: VRDN